We own the CMV vaccine franchise. CMV is a herpes family, which is a problem in both transplant patients and females of child-bearing age. We just did a deal with Astellas, which is a major Japanese company, which is a key player in the transplant market. I will tell you more about that.The second target in the herpes family is Herpes Simplex 2. This is a major problem. It’s a sexually transmitted disease that leads to general lesions. The only antivirals available, we had some very exciting preclinical data in the therapeutic vaccine setting. But these are pipeline programs. We have key validating partnerships with some big pharmaceutical companies. We are one of the few companies by the way which has a GMP manufacturing facility where we have capacity to launch both our CMV and Allovectin programs worldwide. And finally, we have a strong balance sheet. In our recent guidance, we will end the year with about mid-50s million dollars in cash.
Vical Incorporated At Credit Suisse Group Healthcare Conference Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts